Regeneron can open eyes now as Genentech Eylea litigation outcome clears overhang
This article was originally published in Scrip
Executive Summary
Regeneron has partially settled the ongoing patent litigation with Genentech, over US sales of Eyela (aflibercept injection) in eye indications. As a result, ongoing patent infringement litigation in the US District Court for the Southern District of New York is resolved with respect to making, using and selling Eylea for eye uses in the US, although the litigation continues with respect to matters not covered by the agreement.